Clinical trialNCT04851119RecruitingPhase 1/PHASE2Interventional

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

SponsorChildren's Oncology GroupEnrollment147Colorectal CarcinomaEndometrial CarcinomaMelanomaNeuroblastomaOvarian CarcinomaPancreatic Ductal Adenocarcinoma+16 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Sarah B Whittle
Pediatric Early Phase Clinical Trial Network
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Children'S Hospital of Alabama
Birmingham, Alabama, United States
Girish Dhall
Recruiting
Children'S Hospital Los Angeles
Los Angeles, California, United States
Fariba Navid
Recruiting
Children'S Hospital of Orange County
Orange, California, United States
Josephine H. Haduong
Recruiting
Lucile Packard Children'S Hospital Stanford University
Palo Alto, California, United States
Active, not recruiting
Ucsf Medical Center-Mission Bay
San Francisco, California, United States
Kieuhoa T. Vo
Recruiting
Children'S Hospital Colorado
Aurora, Colorado, United States
Margaret E. Macy
Recruiting
Children'S National Medical Center
Washington D.C., District of Columbia, United States
AeRang Kim →
Recruiting
Children'S Healthcare of Atlanta - Arthur M Blank Hospital
Atlanta, Georgia, United States
William T. Cash
Recruiting
Lurie Children'S Hospital-Chicago
Chicago, Illinois, United States
Elizabeth A. Sokol
Recruiting
Riley Hospital for Children
Indianapolis, Indiana, United States
Brian D. Weiss
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Steven G. DuBois →
Recruiting
C S Mott Children'S Hospital
Ann Arbor, Michigan, United States
Rajen Mody
Recruiting
University of Minnesota/masonic Cancer Center
Minneapolis, Minnesota, United States
Robin L. Williams
Recruiting
Washington University School of Medicine
St Louis, Missouri, United States
Shalini Shenoy
Recruiting
Nyp/columbia University Medical Center/herbert Irving Comprehensive Cancer Center
New York, New York, United States
Nobuko Hijiya
Recruiting
Cincinnati Children'S Hospital Medical Center
Cincinnati, Ohio, United States
Joseph G. Pressey
Recruiting
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Jacquelyn Crane
Recruiting
Children'S Hospital of Pittsburgh of Upmc
Pittsburgh, Pennsylvania, United States
Andrew Bukowinski
Recruiting
Saint Jude Children'S Research Hospital
Memphis, Tennessee, United States
Jessica Gartrell
Recruiting
Baylor College of Medicine/dan L Duncan Comprehensive Cancer Center
Houston, Texas, United States
Jennifer H. Foster
Recruiting
Seattle Children'S Hospital
Seattle, Washington, United States
Katherine G. Tarlock
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Tegatrabetan

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 8 Nov 2021
Primary completion: 30 Jun 2028
Completion: 30 Jun 2028
Last update posted: 5 May 2026
Registered enrollment: 147
Registry id: NCT04851119

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.